Home

Turkey Shoot…December Preview

Well, that didn't last long, did it? On Tuesday and Wednesday we saw what looked like a great reversal for biotech. The XBI opened...

Trading Blog, November 23rd, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

TW's Take: this request for additional information certainly increases the risks around the Oleogel PDUFA. Amryt is a reasonably priced stock even if it...

Amryt Pharma plc Announces the Cancellation of Admission of its Ordinary Shares to Trading...

DUBLIN, Ireland, and Boston MA, November 22, 2021, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the “Company”), a global, commercial-stage biopharmaceutical company dedicated to...

Lantern Pharma Announces Share Repurchase Program

TW's Take: shares of LTRN are incredibly cheap and they have funding for at least 3 years, so this move makes a ton of...

The Worst Bull Market Ever

Similar to how the richest billionaires are getting a disproportionate amount of the wealth in the US, the companies they founded are becoming an...

Trading Blog, November 18th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

Atomera Reaches 300 Patents Focused on Perfecting Atomic Level Engineering and Advanced Material Sciences...

TW's Take: we believe that MST will be a game-changing technology that gains board scale acceptance over the coming years. Although it's expensive today,...

Quest Resource Holding Corp. Reports 3rd Quarter 2021 Financial Results

TW's Take: great growth taking place here as Quest is achieving critical mass. Completely off the radar screen ESG opportunity. We expect the stock...

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

TW's Take: Fortress continues to execute well and the sum of the parts here is greater than the current market cap.  NEW YORK, Nov. 15,...

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

TW's Take: a great update. Feels like TFF is on the precipice of big things. In a year, we will have forgotten all about...

Three Non-Biotech Stocks

Higher interest rates and inflation are not good for long-term investment plays. When earnings are years out, a change in the discount rate can...

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

TW's Take: this IPO is a positive for Fortress which owned 70% of DERM prior to the IPO. I believe the pricing is very...

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at...

TW's Take: more positive news on LP-184. This compound, although early in development, looks very promising and has blockbuster potential.  DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern...

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

TW's Take: with a current market cap of $78 million, and funded through approval, the risk/reward here is compelling. I expect the product will...

QUEST RESOURCE HOLDING CORPORATION ACQUIRES ASSET-LIGHT WASTE SERVICES PROVIDER

TW's Take: more positive momentum for their business, this acquisition comes at around 5X EBITDA before synergies, so very reasonably priced with a great...

Notes from INKmune Update

On November 9th, I managed to catch up with Dr. Mark Lowdell, who runs the INKmune cancer program at INmune Bio (INMB). The call...

Trading Blog, November 9th, 2021

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

LexaGene Expands Bio-Pharma Contamination Panel by Adding Test that includes a Biothreat Agent

TW's Take: the functionality of MiQLab allows LexaGene to continually expand the range of the tests it can perform. The market is still awaiting...

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder...

TW's Take: Voriconazole is a great example of a drug whose efficacy and addressable market can be greatly improved by Thin Film Freezing. Looking...

Become a TW Research Member

All our articles are free for everyone to enjoy, however you must register as a user. Please take the time to sign up, it’s free and we do not share your information with anyone.

For those interested in receiving alerts when we buy or sell stocks for our managed accounts, you should consider becoming a premium subscriber. A premium subscription costs $500 per year and subscribers get emails about every transaction taken in our portfolios, including names that have yet to be added to the Tailwinds site.

SIGN ME UP

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.